The round was led by James W. Bullock and William A. Hawkins, III, with participation from Piedmont Capital Partners and existing investors Solas BioVentures.
The company intends to use the funds to continue to develop its device.
CardioNXT is building technologies that enable a better understanding of complex cardiac arrhythmias such as Atrial Fibrillation, and accurately deliver targeted therapy to ectopic source areas within the heart.
The technologies are designed to fit into catheter ablation procedural workflow and reduce the cost of procedures.
FinSMEs
01/06/2017